

# Neuropsychiatric symptoms in Alzheimer's disease

Alzheimer's and Dementia

7, 532-539

DOI: [10.1016/j.jalz.2011.05.2410](https://doi.org/10.1016/j.jalz.2011.05.2410)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prevention of Unnecessary Hospitalization for Patients With Dementia. JAMA - Journal of the American Medical Association, 2012, 307, 197.	3.8	27
2	Diffusion Tensor Imaging of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, 484-488.	0.9	63
3	Nonpharmacologic Management of Behavioral Symptoms in Dementia. JAMA - Journal of the American Medical Association, 2012, 308, 2020.	3.8	382
4	Behavioral Disturbance in Dementia. Current Psychiatry Reports, 2012, 14, 298-309.	2.1	63
5	Addressing the Alzheimer's disease crisis through better understanding, treatment, and eventual prevention of associated neuropsychiatric syndromes. , 2012, 8, 60-64.		23
6	Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms. Epilepsy and Behavior, 2013, 26, 343-351.	0.9	111
7	Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6890-6896.	1.0	20
8	Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia, 2013, 9, S95-S104.e1.	0.4	102
9	Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimer's and Dementia, 2013, 9, 602-608.	0.4	292
10	Subscale Validation of the Neuropsychiatric Inventory Questionnaire: Comparison of Alzheimer's Disease Neuroimaging Initiative and National Alzheimer's Coordinating Center Cohorts. American Journal of Geriatric Psychiatry, 2013, 21, 607-622.	0.6	42
11	Previously not recognized deletion in presenilin-1 (p.Leu174del.) in a patient with early-onset familial Alzheimer's disease. Neuroscience Letters, 2013, 544, 115-118.	1.0	8
12	Broadening the etiological discourse on Alzheimer's disease to include trauma and posttraumatic stress disorder as psychosocial risk factors. Journal of Aging Studies, 2013, 27, 218-224.	0.7	16
13	White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies. Expert Review of Neurotherapeutics, 2013, 13, 483-493.	1.4	68
14	Aripiprazole in the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2013, 14, 459-474.	0.9	46
15	The Cache County Study on Memory in Aging: Factors affecting risk of Alzheimer's disease and its progression after onset. International Review of Psychiatry, 2013, 25, 673-685.	1.4	51
16	Biomarkers of Vascular Risk, Systemic Inflammation, and Microvascular Pathology and Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 363-371.	1.2	73
17	The impact of neuropsychiatric symptoms on caregiver distress and quality of life in persons with dementia in an Asian tertiary hospital memory clinic. International Psychogeriatrics, 2013, 25, 1991-1999.	0.6	52
18	Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics, 2013, 25, 707-719.	0.6	43

#	ARTICLE	IF	CITATIONS
19	The Brazilian version of the Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity in dementia. <i>International Psychogeriatrics</i> , 2013, 25, 1503-1511.	0.6	24
20	Assessment of neuropsychiatric symptoms in dementia: Toward improving accuracy. <i>Dementia E Neuropsychologia</i> , 2013, 7, 244-251.	0.3	11
21	Plasma cortisol in Alzheimer's disease with or without depressive symptoms. <i>Medical Science Monitor</i> , 2013, 19, 681-689.	0.5	41
22	Neuropsychiatric symptoms (NPS) in patients with pure vascular dementia (VaD) and mixed dementia (MD) from a memory outpatient clinic in Southeast Brazil. <i>Dementia E Neuropsychologia</i> , 2013, 7, 263-268.	0.3	4
23	Correlation between neuropsychiatric symptoms and caregiver burden in a population-based sample from São Paulo, Brazil: A preliminary report. <i>Dementia E Neuropsychologia</i> , 2013, 7, 258-262.	0.3	7
24	Behavioral symptoms related to cognitive impairment. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1443.	1.0	86
25	Why looking at the whole hippocampus is not enough: A critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer's disease diagnosis. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 95.	1.8	109
26	Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures. <i>International Psychogeriatrics</i> , 2014, 26, 1805-1848.	0.6	59
27	Behavioral and Psychological Symptoms in Alzheimer's Disease. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	75
29	The Role of the Occupational Therapist in the Management of Neuropsychiatric Symptoms of Dementia in Clinical Settings. <i>Occupational Therapy in Health Care</i> , 2014, 28, 4-20.	0.2	21
30	Factors associated with caregiver readiness to use nonpharmacologic strategies to manage dementia-related behavioral symptoms. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 93-102.	1.3	39
31	Psychiatric Disorders in Dementia. , 2014, , 271-324.		1
32	Neuropsychiatric symptoms in the prodromal stages of dementia. <i>Current Opinion in Psychiatry</i> , 2014, 27, 230-235.	3.1	53
33	Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 435-440.	0.7	18
34	Total Cholesterol and Neuropsychiatric Symptoms in Alzheimer's Disease: The Impact of Total Cholesterol Level and Gender. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 300-309.	0.7	11
35	Unpacking the Evidence: Interventions for Reducing Behavioral and Psychological Symptoms in People with Dementia. <i>Physical and Occupational Therapy in Geriatrics</i> , 2014, 32, 294-309.	0.2	16
36	A Systematic Review of Strategies to Foster Activity Engagement in Persons With Dementia. <i>Health Education and Behavior</i> , 2014, 41, 70S-83S.	1.3	62
37	Personality Changes in Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2014, 28, 261-268.	0.6	15

#	ARTICLE	IF	CITATIONS
38	Psychotropic Drugs in Patients With Alzheimer's Disease: A Longitudinal Study by the Registry of Dementias of Girona (ReDeGi) in Catalonia, Spain. <i>Journal of the American Medical Directors Association</i> , 2014, 15, 497-503.	1.2	8
39	Anxiety Is Not Associated with the Risk of Dementia or Cognitive Decline: The Rotterdam Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1382-1390.	0.6	40
40	Neuropsychiatric symptoms in Alzheimer's disease are related to functional connectivity alterations in the salience network. <i>Human Brain Mapping</i> , 2014, 35, 1237-1246.	1.9	137
41	GSK3 $\beta$ , CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 50, 83-93.	2.5	121
42	Management of Neuropsychiatric Symptoms of Dementia in Clinical Settings: Recommendations from a Multidisciplinary Expert Panel. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 762-769.	1.3	423
43	A Critical Analysis and Adaptation of a Clinical Practice Guideline for the Management of Behavioral Problems in Residents with Dementia in Long-Term Care. <i>Nursing Clinics of North America</i> , 2014, 49, 105-113.	0.7	1
44	Old Worries and New Anxieties: Behavioral Symptoms and Mild Cognitive Impairment in a Population Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 274-284.	0.6	32
45	Psychosis in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2014, 75, 542-552.	0.7	153
46	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2691-2700.	1.5	70
47	Personality and risk of Alzheimer's disease: New data and meta-analysis. <i>Alzheimer's and Dementia</i> , 2014, 10, 179-186.	0.4	228
48	Long-Term Care in North Carolina. <i>North Carolina Medical Journal</i> , 2014, 75, 320-325.	0.1	1
49	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 819-833.	1.2	53
50	The Impact of APOE Status on Relationship of Biomarkers of Vascular Risk and Systemic Inflammation to Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 887-896.	1.2	15
51	Improving Dementia Care Through Behavioral Interventions. <i>North Carolina Medical Journal</i> , 2014, 75, 355-358.	0.1	3
52	Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. <i>International Psychogeriatrics</i> , 2015, 27, 2059-2067.	0.6	22
53	A Review of Pharmacological Treatments for Depression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 15-34.	1.2	7
54	Clinical and Demographic Factors Associated with the Cognitive and Emotional Efficacy of Regular Musical Activities in Dementia. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 767-781.	1.2	39
55	Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease. <i>Harvard Review of Psychiatry</i> , 2015, 23, 377-393.	0.9	33

#	ARTICLE	IF	CITATIONS
56	Evaluation of a hospital-based day-structuring exercise programme on exacerbated behavioural and psychological symptoms in dementia - the exercise carousel: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 228.	0.7	9
57	Caregiver report versus clinician impression: disagreements in rating neuropsychiatric symptoms in Alzheimer's disease patients. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 1230-1237.	1.3	29
58	No pain, functional gain. <i>Pain</i> , 2015, 156, 1377-1378.	2.0	2
59	Psychological and Behavioral Disorders in Dementia. <i>International Journal of Emergency Mental Health</i> , 2015, 18, .	0.3	0
60	Alternative pharmacological treatment options for agitation in Alzheimer's disease. <i>Geriatric Care</i> , 2015, 1, .	0.2	1
61	Alzheimer's Disease associated with Psychiatric Comorbidities. <i>Anais Da Academia Brasileira De Ciencias</i> , 2015, 87, 1461-1473.	0.3	28
62	Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1197-1206.	1.2	33
63	Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer's Disease: From Early to Advanced Pathological Stages. <i>PLoS ONE</i> , 2015, 10, e0130177.	1.1	40
64	Personal Strengths and Health Related Quality of Life in Dementia Caregivers from Latin America. <i>Behavioural Neurology</i> , 2015, 2015, 1-8.	1.1	31
65	Now Is the Time for True Reform of Mental Health Services. <i>JAMA Internal Medicine</i> , 2015, 175, 65.	2.6	0
66	Common Sense: Addressed to Geriatric Psychiatrists on the Subject of Behavioral and Psychological Symptoms of Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1209-1213.	0.6	11
67	Non-pharmacological interventions as a best practice strategy in people with dementia living in nursing homes. A systematic review. <i>European Geriatric Medicine</i> , 2015, 6, 134-150.	1.2	61
68	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. <i>Brain</i> , 2015, 138, 1036-1045.	3.7	67
69	Assessment and management of behavioral and psychological symptoms of dementia. <i>BMJ</i> , 2015, 350, h369-h369.	3.0	801
70	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 7.	3.0	47
71	Corpus Callosum Structure is Topographically Correlated with the Early Course of Cognition and Depression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1097-1108.	1.2	16
72	Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. <i>International Psychogeriatrics</i> , 2015, 27, 181-197.	0.6	29
73	What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. <i>Lancet Psychiatry</i> , 2015, 2, 756-764.	3.7	16

#	ARTICLE	IF	CITATIONS
74	Managing anxiety associated with neurodegenerative disorders. <i>F1000prime Reports</i> , 2015, 7, 05.	5.9	7
75	Cannabinoids in late-onset Alzheimer's disease. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 597-606.	2.3	38
76	Posterior Cortical Atrophy. <i>Psychiatric Clinics of North America</i> , 2015, 38, 211-220.	0.7	27
77	Exercise training for managing behavioral and psychological symptoms in people with dementia: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2015, 24, 274-285.	5.0	82
78	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. <i>Cortex</i> , 2015, 73, 36-61.	1.1	201
79	Neuropsychiatric effects of neurodegeneration of the medial versus lateral ventral prefrontal cortex in humans. <i>Cortex</i> , 2015, 73, 1-9.	1.1	24
80	Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population-based study. <i>Alzheimer's and Dementia</i> , 2015, 11, 917-932.	0.4	70
81	Rescue of impaired late-phase long-term depression in a tau transgenic mouse model. <i>Neurobiology of Aging</i> , 2015, 36, 730-739.	1.5	37
82	Effects of cognitive stimulation on neuropsychiatric symptoms in elderly with Alzheimer's disease: A systematic review. <i>Dementia E Neuropsychologia</i> , 2016, 10, 178-184.	0.3	16
83	Drug Therapy for Behavioral and Psychological Symptoms of Dementia. <i>Current Neuropharmacology</i> , 2016, 14, 307-313.	1.4	29
84	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. <i>Current Alzheimer Research</i> , 2016, 13, 1145-1164.	0.7	50
85	Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 10.	1.7	16
86	Reducing neuropsychiatric symptoms in persons with dementia and associated burden in family caregivers using tailored activities: Design and methods of a randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2016, 49, 92-102.	0.8	56
87	Care-Delivery Interventions to Manage Agitation and Aggression in Dementia Nursing Home and Assisted Living Residents: A Systematic Review and Meta-analysis. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 477-488.	1.3	59
88	Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 545-561.	1.2	26
89	Association of neuropsychiatric syndromes with global clinical deterioration in Alzheimer's disease patients. <i>International Psychogeriatrics</i> , 2016, 28, 779-786.	0.6	27
90	Sensor-based assessment of mobility-related behavior in dementia: feasibility and relevance in a hospital context. <i>International Psychogeriatrics</i> , 2016, 28, 1687-1694.	0.6	29
91	Construct validity and internal consistency of the neuropsychiatric inventory "nursing home (NPI-NH) in German nursing homes. <i>International Psychogeriatrics</i> , 2016, 28, 1017-1027.	0.6	26

#	ARTICLE	IF	CITATIONS
92	Different Patterns of Correlation between Grey and White Matter Integrity Account for Behavioral and Psychological Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 591-604.	1.2	15
93	Shared Genetic Risk Factors for Late-Life Depression and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1-15.	1.2	23
94	Occupational therapists' perspectives on using the remotivation process with clients experiencing dementia. <i>British Journal of Occupational Therapy</i> , 2016, 79, 92-101.	0.5	2
95	Feasibility of the Tailored Activity Program for Hospitalized (TAP-H) Patients With Behavioral Symptoms. <i>Gerontologist</i> , The, 2017, 57, gnw052.	2.3	23
96	Aberrant functional connectivity differentiates retrosplenial cortex from posterior cingulate cortex in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 44, 114-126.	1.5	63
97	Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 430-440.	2.2	32
98	Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tau:APP transgenic model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2016, 96, 171-185.	2.1	19
99	Considering new treatment paradigms for neuropsychiatric symptoms of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1031-1032.	0.4	2
100	Translation of the Care of Persons with Dementia in their Environments (COPE) intervention in a publicly-funded home care context: Rationale and research design. <i>Contemporary Clinical Trials</i> , 2016, 49, 155-165.	0.8	42
101	Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease. <i>Human Brain Mapping</i> , 2016, 37, 4234-4247.	1.9	55
102	Charting the chemical space around the (iso)indoline scaffold, a comprehensive approach towards multitarget directed ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4211-4215.	1.0	3
103	EL ROL DE LA EVALUACIÓN NEUROPSICOLÓGICA EN EL DIAGNÓSTICO Y EN EL SEGUIMIENTO DE LAS DEMENCIAS. <i>Revista Médica Clínica Las Condes</i> , 2016, 27, 319-331.	0.2	3
104	Brain Regions Involved in Arousal and Reward Processing are Associated with Apathy in Alzheimer's Disease and Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 551-558.	1.2	30
105	Examining the Relationship Between Autobiographical Memory Impairment and Carer Burden in Dementia Syndromes. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 237-248.	1.2	20
106	Managing behavioral disturbances in a patient with dementia. <i>Nurse Practitioner</i> , 2016, 41, 50-54.	0.2	0
107	Improving Management of Behavioral and Psychological Symptoms of Dementia in Acute Care. <i>Nursing Administration Quarterly</i> , 2016, 40, 244-254.	0.9	17
108	Impact of caregiver readiness on outcomes of a nonpharmacological intervention to address behavioral symptoms in persons with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1056-1063.	1.3	19
109	Speech and language impairments in dementia. <i>Journal of Applied Biomedicine</i> , 2016, 14, 97-103.	0.6	61

#	ARTICLE	IF	CITATIONS
110	Drugs related to monoamine oxidase activity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 69, 112-124.	2.5	60
111	Biomarkers of aggression in dementia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 69, 125-130.	2.5	20
112	Microglial dysfunction connects depression and Alzheimer's disease. <i>Brain, Behavior, and Immunity</i> , 2016, 55, 151-165.	2.0	100
113	Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrine. <i>Neuropharmacology</i> , 2016, 101, 76-86.	2.0	46
114	Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 70-80.	0.6	39
115	Disrupted-in-Schizophrenia-1 Attenuates Amyloid- $\beta$ Generation and Cognitive Deficits in APP/PS1 Transgenic Mice by Reduction of $\beta$ -Site APP-Cleaving Enzyme 1 Levels. <i>Neuropsychopharmacology</i> , 2016, 41, 440-453.	2.8	16
116	Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 195-202.	0.4	493
117	Effectiveness of Expanded Implementation of STAR-VA for Managing Dementia-Related Behaviors Among Veterans. <i>Gerontologist</i> , The, 2016, 56, 126-134.	2.3	44
118	Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 164-174.	1.3	66
119	Dysfunction of ventrolateral striatal dopamine receptor type 2-expressing medium spiny neurons impairs instrumental motivation. <i>Nature Communications</i> , 2017, 8, 14304.	5.8	46
120	Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017, 30, 26-49.	1.2	46
121	Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. <i>Neurology</i> , 2017, 88, 1814-1821.	1.5	61
122	Alterations in protein phosphorylation in the amygdala of the 5XFamilial Alzheimer's disease animal model. <i>Journal of Pharmacological Sciences</i> , 2017, 133, 261-267.	1.1	11
123	Elevated emotional contagion in a mouse model of Alzheimer's disease is associated with increased synchronization in the insula and amygdala. <i>Scientific Reports</i> , 2017, 7, 46262.	1.6	18
124	Detection and Management of Preexisting Cognitive Impairment in the Critical Care Unit. <i>Critical Care Clinics</i> , 2017, 33, 441-459.	1.0	5
125	Physical restraints and associations with neuropsychiatric symptoms and personal characteristics in residential care: a cross-sectional study. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1418-1424.	1.3	5
126	WeCareAdvisor, <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 263-270.	0.6	28
127	Enhancing Communication in Adults with Dementia and Age-Related Hearing Loss. <i>Seminars in Hearing</i> , 2017, 38, 177-183.	0.5	13



#	ARTICLE	IF	CITATIONS
128	Neuropsychiatric Symptoms and Cognitive Impairment: Understanding the Importance of Co-Morbid Symptoms. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 141-153.	1.2	37
129	Distress Associated with Dementia-Related Psychosis and Agitation in Relation to Healthcare Utilization and Costs. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1074-1082.	0.6	53
130	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 387-393.	1.2	11
131	Background characteristics and treatment-related factors associated with treatment success or failure in a non-pharmacological intervention for dementia caregivers. <i>International Psychogeriatrics</i> , 2017, 29, 1005-1014.	0.6	6
132	Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. <i>BMJ Open</i> , 2017, 7, e012759.	0.8	356
133	Mandibular movements and bite force in Alzheimer's disease before and after new denture insertion. <i>Journal of Oral Rehabilitation</i> , 2017, 44, 178-186.	1.3	11
134	Novel Vilazodone-Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2708-2721.	1.7	32
135	Associations of Neuropsychiatric Symptoms and Antidepressant Prescription with Survival in Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 1076-1081.	1.2	26
136	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7483-7501.	2.9	25
137	Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 440-449.	1.8	240
138	A randomized trial of a web-based platform to help families manage dementia-related behavioral symptoms: The WeCareAdvisor. <i>Contemporary Clinical Trials</i> , 2017, 62, 27-36.	0.8	15
139	Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 483-493.	1.2	30
140	Trajectories of depressive symptoms and their relationship to the progression of dementia. <i>Journal of Affective Disorders</i> , 2017, 222, 146-152.	2.0	39
141	Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study. <i>International Psychogeriatrics</i> , 2017, 29, 1723-1733.	0.6	15
142	Behavior Symptoms in Primary Progressive Aphasia Variants. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2017, , 27-43.	0.3	1
143	Mild cognitive impairment and risk of depression and anxiety: A population-based study. <i>Alzheimer's and Dementia</i> , 2017, 13, 130-139.	0.4	72
144	Management of older adults with dementia who present to emergency services with neuropsychiatric symptoms. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1233-1240.	1.3	14
145	A supporting system for quick dementia screening using PIR motion sensor in smart home. , 2017, , .		6

#	ARTICLE	IF	CITATIONS
146	Dementia-related agitation: a review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy. <i>Translational Psychiatry</i> , 2017, 7, e1250-e1250.	2.4	81
147	Development and pilot testing of a decision aid for the initiation of antipsychotic medications in persons with dementia in long-term care using a systematic approach: a study protocol. <i>BMJ Open</i> , 2017, 7, e018769.	0.8	8
148	Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAYFLOWER RoAD). <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1217-1228.	1.2	33
149	Physicochemical Properties for Potential Alzheimer's Disease Drugs. , 2017, , 59-82.		0
150	Computer-Based Training Programs for Older People with Mild Cognitive Impairment and/or Dementia. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 262.	1.0	48
151	Aerobic exercise improves quality of life, psychological well-being and systemic inflammation in subjects with Alzheimer's disease. <i>African Health Sciences</i> , 2017, 16, 1045.	0.3	62
152	Utility of the Neuropsychiatric Inventory Questionnaire (NPI-Q) in the assessment of a sample of patients with Alzheimer's disease in Chile. <i>Dementia E Neuropsychologia</i> , 2017, 11, 129-136.	0.3	30
153	Cognitive-Behavioral Therapy in Older Adults. , 2017, , 223-255.		28
154	Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia. <i>International Psychogeriatrics</i> , 2018, 30, 167-169.	0.6	13
155	Commentary on Apathy as a Model for Investigating Behavioral and Psychological Symptoms in Dementia. <i>Journal of the American Geriatrics Society</i> , 2018, 66, S13-S16.	1.3	6
156	Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1445-1456.	1.1	41
157	Caregiver Reactions to Dementia Symptoms: Effects on Coping Repertoire and Mental Health. <i>Issues in Mental Health Nursing</i> , 2018, 39, 382-387.	0.6	5
158	The Progression of Neuropsychiatric Symptoms in Alzheimer's Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1367-1376.	1.2	24
159	Behavioural intervention to reduce resistance in those attending adult day care centres: PROCENDIAS study protocol for a randomized clinical trial. <i>Journal of Advanced Nursing</i> , 2018, 74, 1402-1411.	1.5	2
160	Targeting Behavioral Symptoms and Functional Decline in Dementia: A Randomized Clinical Trial. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 339-345.	1.3	71
161	Managing Behavioral and Psychological Symptoms of Dementia. <i>Psychiatric Clinics of North America</i> , 2018, 41, 127-139.	0.7	58
162	Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia. <i>Current Opinion in Psychiatry</i> , 2018, 31, 140-146.	3.1	15
163	Cracking novel shared targets between epilepsy and Alzheimer's disease: need of the hour. <i>Reviews in the Neurosciences</i> , 2018, 29, 425-442.	1.4	16

#	ARTICLE	IF	CITATIONS
164	Behavioral and Neuropsychiatric Disorders in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 899-910.	1.2	40
165	Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S313-S327.	1.2	31
166	The stability of neuropsychiatric subsyndromes in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 880-888.	0.4	24
167	Association of the Centers for Medicare & Medicaid Services' National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014. <i>JAMA Internal Medicine</i> , 2018, 178, 640.	2.6	90
168	Outcomes of a Two-Component Intervention on Behavioral Symptoms in Persons With Dementia and Symptom Response in Their Caregivers. <i>Journal of Applied Gerontology</i> , 2018, 37, 570-594.	1.0	8
169	Quality of Life in relation to neuropsychiatric symptoms in Alzheimer's disease: 5-year prospective ALSOVA cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 47-57.	1.3	57
170	Differential associations between sensory loss and neuropsychiatric symptoms in adults with and without a neurocognitive disorder. <i>International Psychogeriatrics</i> , 2018, 30, 261-272.	0.6	9
171	A systematic review of non-pharmacological treatments for apathy in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, e177-e192.	1.3	52
172	Neuropsychiatric symptoms as risk factors of dementia in a Mexican population: A 10/66 Dementia Research Group study. <i>Alzheimer's and Dementia</i> , 2018, 14, 271-279.	0.4	35
173	Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2018, 30, 103-113.	0.6	99
174	Self-reported personality traits are prospectively associated with proxy-reported behavioral and psychological symptoms of dementia at the end of life. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 489-494.	1.3	21
175	Noncognitive Behavioral Changes Associated With Alzheimer's Disease: Implications of Neuroimaging Findings. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2018, 30, 14-21.	0.9	20
176	Alzheimer Disease. <i>Journal for Nurse Practitioners</i> , 2018, 14, 129-135.	0.4	64
177	Animal-assisted intervention for individuals with cognitive impairment: A meta-analysis of randomized controlled trials and quasi-randomized controlled trials. <i>Psychiatry Research</i> , 2018, 260, 418-427.	1.7	41
178	Reliability and Validity of the Care Plan Checklist for Evidence of Person-Centered Approaches for Behavioral and Psychological Symptoms Associated With Dementia. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 613-618.	1.2	16
179	Relationship between the number of behavioral symptoms in dementia and caregiver distress: what is the tipping point?. <i>International Psychogeriatrics</i> , 2018, 30, 1099-1107.	0.6	43
180	Crosstalk between endoplasmic reticulum stress and brain inflammation in Alzheimer's disease. <i>Neuropharmacology</i> , 2018, 136, 350-360.	2.0	61
181	Temporal Associations between Caregiving Approach, Behavioral Symptoms and Observable Indicators of Aspiration in Nursing Home Residents with Dementia. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 400-406.	1.5	25

#	ARTICLE	IF	CITATIONS
182	Brain Perfusion Correlates of Apathy in Alzheimer's Disease. <i>Dementia and Neurocognitive Disorders</i> , 2018, 17, 50.	0.4	8
183	â€œThis Condition isn't Going to get any Better so I can't see why we're Prolonging itâ€ Risks and Benefits of using Empirical Research to Inform Normative Decisions Concerning End-of-Life Care. <i>Journal of Disability and Religion</i> , 2018, 22, 283-297.	0.2	1
184	Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimerâ€™s Disease: A Case Report. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1363-1369.	1.2	5
185	Adaptive interaction as a method of non-verbal communication in individuals with dementia. <i>Practice Nursing</i> , 2018, 29, 176-180.	0.1	1
186	Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimerâ€™s disease: a network meta-analysis of 41 randomized controlled trials. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 126.	3.0	97
187	Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder. <i>Mental Health Clinician</i> , 2018, 8, 284-293.	0.5	11
188	Radiomic Features of Hippocampal Subregions in Alzheimerâ€™s Disease and Amnestic Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 290.	1.7	86
189	Rehabilitation to live better with dementia. <i>Geriatrics and Gerontology International</i> , 2018, 18, 1529-1536.	0.7	35
190	Effects of Physical Exercise on Depressive Symptoms in Patients With Cognitive Impairment. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 809-823.	0.5	22
191	Cerebrospinal Fluid Orexin Levels and Nocturnal Sleep Disruption in Alzheimerâ€™s Disease Patients Showing Neuropsychiatric Symptoms. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 993-999.	1.2	22
192	Neuropathologic Correlates of Psychiatric Symptoms in Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 115-126.	1.2	133
193	Multinutrient Intervention in the Prevention and Treatment of Dementia. , 2018, , 341-351.		2
194	People with dementia getting lost in Australia: Dementiaâ€™related missing person reports in the media. <i>Australasian Journal on Ageing</i> , 2018, 37, E97-E103.	0.4	12
195	Neuropsychiatric Symptoms of Major or Mild Neurocognitive Disorders. , 2018, , 467-494.		0
196	The cholinergic system in the pathophysiology and treatment of Alzheimerâ€™s disease. <i>Brain</i> , 2018, 141, 1917-1933.	3.7	1,008
197	Imaging Care Requirements: Use of Functional Neuroimaging to Predict Dementia Caregiver Burden. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 180-189.	0.6	0
198	Increased risk of dementia in patients with Schizophrenia: A population-based cohort study in Taiwan. <i>European Psychiatry</i> , 2018, 53, 7-16.	0.1	32
199	Neuropsychiatric Symptoms and Caregiver Burden in Individuals With Alzheimerâ€™s Disease: The TEAM-AD VA Cooperative Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2018, 31, 177-185.	1.2	39

#	ARTICLE	IF	CITATIONS
200	Dementia Care at End of Life: Current Approaches. <i>Current Psychiatry Reports</i> , 2018, 20, 50.	2.1	20
201	Effect of the WeCareAdvisor <sup>®</sup> on family caregiver outcomes in dementia: a pilot randomized controlled trial. <i>BMC Geriatrics</i> , 2018, 18, 113.	1.1	45
202	mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2226.	1.8	84
203	Early Life Stress-Related Elevations in Reaction Time Variability Are Associated with Brain Volume Reductions in HIV+ Adults. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 6.	1.0	10
204	Alzheimer's disease: Only prevention makes sense. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13005.	1.7	41
205	Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols. <i>Frontiers in Pharmacology</i> , 2018, 9, 867.	1.6	29
206	Cognitive Therapy for Dementia Patients: A Systematic Review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 1-26.	0.7	48
207	Support vector machine-based classification of neuroimages in Alzheimer's disease: direct comparison of FDG-PET, rCBF-SPECT and MRI data acquired from the same individuals. <i>Revista Brasileira De Psiquiatria</i> , 2018, 40, 181-191.	0.9	29
208	Planning for an uncertain future in progressive neurological disease: a qualitative study of patient and family decision-making with a focus on eating and drinking. <i>BMC Neurology</i> , 2018, 18, 115.	0.8	21
209	Can nonalcoholic beer, silicon and hops reduce the brain damage and behavioral changes induced by aluminum nitrate in young male Wistar rats?. <i>Food and Chemical Toxicology</i> , 2018, 118, 784-794.	1.8	9
210	An intervention to reduce neuropsychiatric symptoms and caregiver burden in dementia: preliminary results from a randomized trial of the tailored activity program's outpatient version. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1301-1307.	1.3	45
211	Assessing mild behavioral impairment with the mild behavioral impairment checklist in people with subjective cognitive decline. <i>International Psychogeriatrics</i> , 2019, 31, 231-239.	0.6	80
212	When Less is More, but Still Not Enough: Why Focusing on Limiting Antipsychotics in People With Dementia Is the Wrong Policy Imperative. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1074-1079.	1.2	49
213	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298.		2
214	Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer's disease and depressive disorder. <i>Mitochondrion</i> , 2019, 48, 67-77.	1.6	40
215	Translational approach to apathy-like behavior in mice: From the practical point of view. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 685-689.	1.0	2
216	Therapeutic Targeting of Casein Kinase 1 $\beta$ in an Alzheimer's Disease Mouse Model. <i>Journal of Proteome Research</i> , 2019, 18, 3383-3393.	1.8	25
217	Management of Behavioral and Psychological Symptoms of Dementia. <i>Current Psychiatry Reports</i> , 2019, 21, 66.	2.1	148

#	ARTICLE	IF	CITATIONS
218	Self-Reported Personality Traits and Informant-Rated Cognition: A 10-Year Prospective Study. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 181-190.	1.2	10
219	Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice. <i>Frontiers in Pharmacology</i> , 2019, 10, 1044.	1.6	33
220	Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer's Disease: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1108.	1.6	14
221	Tau and Amyloid- $\beta$ Pathology in Japanese Forensic Autopsy Series Under 40 Years of Age: Prevalence and Association with APOE Genotype and Suicide Risk. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 641-652.	1.2	8
222	Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer's Disease/Mild Cognitive Impairment: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 477-501.	1.2	25
223	Altered Cingulate Cortex Functional Connectivity in Normal Aging and Mild Cognitive Impairment. <i>Frontiers in Neuroscience</i> , 2019, 13, 857.	1.4	43
224	Differential Diagnosis of Cognitive Impairment in Bipolar Disorder: A Case Report. <i>Journal of Clinical Case Reports</i> , 2019, 09, .	0.0	0
225	Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease: A systematic literature review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 346-359.	2.9	29
226	Novel pyridazinone derivatives as butyrylcholinesterase inhibitors. <i>Bioorganic Chemistry</i> , 2019, 92, 103304.	2.0	8
227	Neuropsychiatric Manifestations of Cognitively Advanced Idiopathic Normal Pressure Hydrocephalus. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 8, 467-475.	0.6	9
228	Terapias no farmacológicas en demencia y agitación. <i>FMC Formación Médica Continuada En Atención Primaria</i> , 2019, 26, 43-49.	0.0	0
229	The Neuropsychiatric Inventory-Diary Rating Scale (NPI-Diary): A Method for Improving Stability in Assessing Neuropsychiatric Symptoms in Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 8, 306-320.	0.6	12
230	Meta-analysis of expression and methylation signatures indicates a stress-related epigenetic mechanism in multiple neuropsychiatric disorders. <i>Translational Psychiatry</i> , 2019, 9, 32.	2.4	11
231	Adopting a Diary to Support an Ecological Assessment of Neuropsychiatric Symptoms of Dementia. <i>Journal of Nutrition, Health and Aging</i> , 2019, 23, 614-616.	1.5	4
232	Collapsin response mediator protein 5 (CRMP5) causes social deficits and accelerates memory loss in an animal model of Alzheimer's disease. <i>Neuropharmacology</i> , 2019, 157, 107673.	2.0	14
233	Co-Creating Platform Governance Models Using Boundary Resources: a Case Study from Dementia Care Services. <i>Computer Supported Cooperative Work</i> , 2019, 28, 549-589.	1.9	4
235	Tau binding protein CAPON induces tau aggregation and neurodegeneration. <i>Nature Communications</i> , 2019, 10, 2394.	5.8	59
236	Alzheimer's disease and symbiotic microbiota: an evolutionary medicine perspective. <i>Annals of the New York Academy of Sciences</i> , 2019, 1449, 3-24.	1.8	45

#	ARTICLE	IF	CITATIONS
237	Overcoming a Bad Day: a Qualitative Look into the Dementia Caregiving Experiences of Mexican-Origin Women in East Los Angeles. <i>Journal of Cross-Cultural Gerontology</i> , 2019, 34, 373-384.	0.5	5
238	Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 123.	1.4	49
239	Age and sex differences in motivation and spatial working memory in 3xTg-AD mice in the Hebb-Williams maze. <i>Behavioural Brain Research</i> , 2019, 370, 111937.	1.2	16
240	Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 48.	3.0	14
241	Von Economo Neurons in Behavioral Variant Frontotemporal Dementia with Underlying Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 963-967.	1.2	10
242	Comparing the effect of the novel ionic cocrystal of lithium salicylate proline (LISPRO) with lithium carbonate and lithium salicylate on memory and behavior in female APPswe/PS1dE9 Alzheimer's mice. <i>Journal of Neuroscience Research</i> , 2019, 97, 1066-1080.	1.3	7
243	Effect of depressive disorder on cognitive decline. <i>Archives of Gerontology and Geriatrics</i> , 2019, 83, 211-216.	1.4	5
244	Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA. <i>Drugs in R and D</i> , 2019, 19, 93-115.	1.1	39
245	Impact of three dementia-related behaviors on caregiver depression: The role of rejection of care, aggression, and agitation. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 966-973.	1.3	13
246	TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER'S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDY. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2019, 6, 1-6.	1.5	23
247	Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 333-339.	1.2	95
248	Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study. <i>Neurological Sciences</i> , 2019, 40, 1377-1382.	0.9	27
249	Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 164-169.	1.2	11
250	Neurocognitive Disorders and Neuropsychiatric Symptoms. , 2019, , 39-69.		0
251	On the central role of mitochondria dysfunction and oxidative stress in Alzheimer's disease. <i>Neurological Sciences</i> , 2019, 40, 1527-1540.	0.9	76
252	Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia. <i>Frontiers in Pharmacology</i> , 2019, 10, 1398.	1.6	17
253	APOE ε4/ε4 Is Associated with Aberrant Motor Behavior Through Both Lewy Body and Cerebral Amyloid Angiopathy Pathology in High Alzheimer's Disease Pathological Load. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1077-1087.	1.2	6
254	Early Cognitive and Behavioral Deficits in Mouse Models for Tauopathy and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 335.	1.7	28

#	ARTICLE	IF	CITATIONS
255	Neuropsychiatric Symptoms in Alzheimer's Disease Are the Main Determinants of Functional Impairment in Advanced Everyday Activities. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 381-392.	1.2	25
256	Comparison of the efficacy of gesture-verbal treatment and doll therapy for managing neuropsychiatric symptoms in older patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1308-1315.	1.3	20
257	Meditation on the Soles of the Feet Practice Provides Some Control of Aggression for Individuals with Alzheimer's Disease. <i>Mindfulness</i> , 2019, 10, 1232-1242.	1.6	11
258	Repetitive Transcranial Magnetic Stimulation Improves Executive Function and Music Rhythm. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 178-180.	0.9	1
259	Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer's disease and schizophrenia: Insights from studies in patient populations and animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 112-137.	2.9	56
260	Developing a Pain Intensity Measure for Persons with Dementia: Initial Construction and Testing. <i>Pain Medicine</i> , 2019, 20, 1078-1092.	0.9	11
261	A systematic review of electronic assistive technology within supporting living environments for people with dementia. <i>Dementia</i> , 2019, 18, 2371-2435.	1.0	49
262	Prevalence of delusions in drug-naïve Alzheimer disease patients: A meta-analysis. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1287-1293.	1.3	7
263	Caregivers' emotional distress due to neuropsychiatric symptoms of persons with amnesic mild cognitive impairment or Alzheimer's disease. <i>Aging and Mental Health</i> , 2020, 24, 423-430.	1.5	14
264	Are neuropsychiatric symptoms modifiable risk factors for cognitive decline in Alzheimer's disease and vascular dementia?. <i>British Journal of Psychiatry</i> , 2020, 216, 1-3.	1.7	11
265	Findings From a Prospective Randomized Controlled Trial of an Individualized Music Listening Program for Persons With Dementia. <i>Journal of Applied Gerontology</i> , 2020, 39, 567-575.	1.0	25
266	Effects of Inappropriate Sexual Behaviors and Neuropsychiatric Symptoms of Patients With Alzheimer Disease and Caregivers' Depression on Caregiver Burden. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 243-249.	1.2	7
267	Optimizing Prescribing of Antipsychotics in Long-Term Care (OPAL): A Stepped-Wedge Trial. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 381-387.e3.	1.2	6
268	A Fast and Low-Cost Repetitive Movement Pattern Indicator for Massive Dementia Screening. <i>IEEE Transactions on Automation Science and Engineering</i> , 2020, 17, 771-783.	3.4	7
269	Neuropsychiatric symptoms as predictors of conversion from MCI to dementia: a machine learning approach. <i>International Psychogeriatrics</i> , 2020, 32, 381-392.	0.6	29
270	Neuropsychiatric symptoms and activities of daily living in Alzheimer's disease: ALSOVA 5-year follow-up study. <i>International Psychogeriatrics</i> , 2020, 32, 741-751.	0.6	23
271	Psychotherapy and Cognitive Disorders. , 2020, , 139-149.		1
272	Seeking for potential pathogenic genes of major depressive disorder in the Gene Expression Omnibus database. <i>Asia-Pacific Psychiatry</i> , 2020, 12, e12379.	1.2	6



#	ARTICLE	IF	CITATIONS
273	Does the neuropsychiatric inventory predict progression from mild cognitive impairment to dementia? A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2020, 58, 101004.	5.0	17
274	The Specialized Early Care for Alzheimer's method of caring for people with dementia: an investigation of what works and how. <i>Scandinavian Journal of Caring Sciences</i> , 2020, 34, 736-744.	1.0	3
275	Physical exercise attenuates cognitive decline and reduces behavioural problems in people with mild cognitive impairment and dementia: a systematic review. <i>Journal of Physiotherapy</i> , 2020, 66, 9-18.	0.7	116
276	A cluster-randomized crossover trial of Montessori activities delivered by family carers to nursing home residents with behavioral and psychological symptoms of dementia. <i>International Psychogeriatrics</i> , 2020, 32, 347-358.	0.6	20
277	Methylphenidate and Rosmarinus officinalis improves cognition and regulates inflammation and synaptic gene expression in Aβ1-3-induced neurotoxicity mouse model. <i>Molecular Biology Reports</i> , 2020, 47, 7861-7870.	1.0	7
278	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers" results from the DELCODE study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 131.	3.0	17
279	Endocannabinoid system alterations in Alzheimer's disease: A systematic review of human studies. <i>Brain Research</i> , 2020, 1749, 147135.	1.1	23
280	Cognitive Impairment in the 3xTg-AD Mouse Model of Alzheimer's Disease is Affected by Aβ2-ImmunoTherapy and Cognitive Stimulation. <i>Pharmaceutics</i> , 2020, 12, 944.	2.0	17
281	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 153.	3.0	9
282	Cognitive Reserve, Leisure Activity, and Neuropsychological Profile in the Early Stage of Cognitive Decline. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 590607.	1.7	20
283	Effectiveness of online dementia caregivers training programs: A systematic review. <i>Geriatric Nursing</i> , 2020, 41, 921-935.	0.9	37
284	Family Relationships and Alzheimer's Disease: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1595-1608.	1.2	8
285	White matter hyperintensities and neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102367.	1.4	28
286	Palliative Care in Advanced Dementia. <i>Frontiers in Psychiatry</i> , 2020, 11, 699.	1.3	52
287	The Role of Caregivers' Sleep Problems in the Association between Behavioral Symptoms of Dementia and Caregiving Depression and Anxiety. <i>Behavioral Sleep Medicine</i> , 2021, 19, 640-651.	1.1	9
289	Amyloid PET imaging in clinical practice. <i>Practical Neurology</i> , 2020, 20, 451-462.	0.5	28
290	Alzheimer's Dementia. , 2020, , 1-19.		0
291	Primary Progressive Aphasia. , 2020, , 20-42.		1

#	ARTICLE	IF	CITATIONS
293	Mild Cognitive Impairment. , 2020, , 68-94.		0
294	Parkinsonâ€™s Disease Dementia. , 2020, , 95-132.		0
295	Huntingtonâ€™s Disease. , 2020, , 133-166.		0
304	Memantine, Donepezil, or Combination Therapyâ€”What is the best therapy for Alzheimerâ€™s Disease? A Network Meta-Analysis. Brain and Behavior, 2020, 10, e01831.	1.0	55
305	Considering Psychodynamic Therapy for Older Adults. Psychodynamic Psychiatry, 2020, 48, 152-162.	0.1	1
306	THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINE. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-5.	1.5	7
307	Mental Health Status of Psychogeriatric Patients During the 2019 New Coronavirus Disease (COVID-19) Pandemic and Effects on Caregiver Burden. Frontiers in Psychiatry, 2020, 11, 578672.	1.3	24
308	Implementing a Reablement Intervention, â€œCare of People With Dementia in Their Environments (COPE)â€: A Hybrid Implementation-Effectiveness Study. Gerontologist, The, 2021, 61, 965-976.	2.3	17
309	More evidence for etiologic heterogeneity of dementia in the oldest-old: a Precision Medicine approach is needed to move treatment development forward. International Psychogeriatrics, 2020, 32, 563-565.	0.6	0
310	Verapamil and Alzheimerâ€™s Disease: Past, Present, and Future. Frontiers in Pharmacology, 2020, 11, 562.	1.6	16
311	Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimerâ€™s disease mice. Translational Neurodegeneration, 2020, 9, 18.	3.6	12
312	In vivo MRI Structural and PET Metabolic Connectivity Study of Dopamine Pathways in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 75, 1003-1016.	1.2	23
313	Insula and Amygdala Atrophy Are Associated With Functional Impairment in Subjects With Presbycusis. Frontiers in Aging Neuroscience, 2020, 12, 102.	1.7	20
314	A contextual model of care for persons with dementia. , 2020, , 245-269.		1
315	Neuropsychiatric Aspects of Alzheimer Dementia. Psychiatric Clinics of North America, 2020, 43, 383-397.	0.7	3
316	The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimerâ€™s Disease During the COVID-19 Crisis. Journal of Alzheimer's Disease, 2020, 76, 41-47.	1.2	115
317	A Critical Review of Behavioral and Emotional Disinhibition. Journal of Nervous and Mental Disease, 2020, 208, 344-351.	0.5	7
318	Resting-state fMRI analysis in apathetic Alzheimer's disease. Diagnostic and Interventional Radiology, 2020, 26, 363-369.	0.7	12

#	ARTICLE	IF	CITATIONS
319	Altered phobic reactions in frontotemporal dementia: A behavioural and neuroanatomical analysis. <i>Cortex</i> , 2020, 130, 100-110.	1.1	4
320	Physical and Pharmacological Restraints in Hospital Care: Protocol for a Systematic Review. <i>Frontiers in Psychiatry</i> , 2019, 10, 921.	1.3	13
321	Shared genetic etiology underlying Alzheimer's disease and major depressive disorder. <i>Translational Psychiatry</i> , 2020, 10, 88.	2.4	45
322	Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer's Disease: Insights From Preclinical Models, Clinical Data, and Future Directions. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 56.	1.7	11
323	Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, 1280-1292.	0.4	15
324	Virtual reality and dementia: A bibliometric analysis. <i>European Journal of Psychiatry</i> , 2020, 34, 120-131.	0.7	16
325	Resident-to-resident aggression in Norwegian nursing homes: a cross-sectional exploratory study. <i>BMC Geriatrics</i> , 2020, 20, 222.	1.1	13
326	Ongoing research protocols for the pharmacological treatment of neuropsychiatric symptoms in dementia. <i>Journal of Frailty &amp; Aging</i> , 2021, 10, 1-9.	0.8	4
327	Rosmarinus officinalis Essential Oil Improves Scopolamine-Induced Neurobehavioral Changes via Restoration of Cholinergic Function and Brain Antioxidant Status in Zebrafish ( <i>Danio rerio</i> ). <i>Antioxidants</i> , 2020, 9, 62.	2.2	30
328	Does Telehealth Delivery of a Dyadic Dementia Care Program Provide a Noninferior Alternative to Face-To-Face Delivery of the Same Program? A Randomized, Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 673-682.	0.6	43
329	Neuroanatomical associations of depression, anxiety and apathy neuropsychiatric symptoms in patients with Alzheimer's disease. <i>Acta Neurologica Belgica</i> , 2021, 121, 1469-1480.	0.5	12
330	Neuropsychiatric symptoms as prognostic makers for the elderly with mild cognitive impairment: a meta-analysis. <i>Journal of Affective Disorders</i> , 2020, 271, 185-192.	2.0	18
331	Embarking on a memory assessment voices of older persons living with memory impairment. <i>Dementia</i> , 2021, 20, 717-733.	1.0	4
332	Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>European Journal of Epidemiology</i> , 2021, 36, 89-101.	2.5	26
333	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 1.	3.6	23
334	Neuropsychiatric Symptoms in Patients With Alzheimer's Disease During SARS-COV-2 Pandemic in Peru. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2021, 36, 153331752110390.	0.9	5
335	Potential of Naturally Derived Alkaloids as Multi-Targeted Therapeutic Agents for Neurodegenerative Diseases. <i>Molecules</i> , 2021, 26, 728.	1.7	43
336	Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury. <i>Progress in Brain Research</i> , 2021, 265, 139-230.	0.9	9

#	ARTICLE	IF	CITATIONS
337	Psychoses Due to Medical Illness or Iatrogenesis. , 2021, , 125-141.		0
338	Female dominance of both spatial cognitive dysfunction and neuropsychiatric symptoms in a mouse model of Alzheimer's disease. <i>Experimental Animals</i> , 2021, 70, 398-405.	0.7	4
339	Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. <i>Progress in Brain Research</i> , 2021, 265, 1-97.	0.9	8
340	Machine Learning Methods with Decision Forests for Parkinson's Detection. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 581.	1.3	30
341	Relation among Caregivers' Burden, Abuse and Behavioural Disorder in People with Dementia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1263.	1.2	12
342	Sex differences in psychiatric disorders and their implication for dementia. , 2021, , 187-206.		0
343	Use of psychiatric medication in three Arctic nursing homes: association with dementia and psychiatric symptoms. <i>International Journal of Circumpolar Health</i> , 2021, 80, 1920252.	0.5	0
344	Neuropsychiatric Symptoms Assessment: Cross-cultural Adaptation and Validation of the Portuguese Abe's BPSD Score (ABS). <i>Clinical Gerontologist</i> , 2022, 45, 591-605.	1.2	1
345	Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 430-450.	0.8	29
346	Frequency and Predictors of Traumatic Encephalopathy Syndrome in a Prospective Cohort of Retired Professional Athletes. <i>Frontiers in Neurology</i> , 2021, 12, 617526.	1.1	10
347	Group Music Intervention Using Percussion Instruments to Reduce Anxiety Among Elderly Male Veterans with Alzheimer Disease. <i>Medical Science Monitor</i> , 2021, 27, e928714.	0.5	5
348	Association of Dementia-Related Psychosis With Long-term Care Use and Death. <i>Neurology</i> , 2021, 96, e1620-e1631.	1.5	6
349	Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1-27.	1.2	27
350	Behavioural and psychological symptoms of dementia: a new framework for holistic understanding and non-pharmacological management. <i>BJ Psych Advances</i> , 2022, 28, 11-20.	0.5	10
351	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. <i>Translational Neurodegeneration</i> , 2021, 10, 11.	3.6	17
352	The Relationship Between Anxiety and Alzheimer's Disease1. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 171-177.	1.2	53
353	Pain in persons with dementia and the direct and indirect impacts on caregiver burden. <i>Geriatric Nursing</i> , 2021, 42, 366-371.	0.9	6
354	Cannabis Use in Older Adults: A Perspective. <i>Harvard Review of Psychiatry</i> , 2021, 29, 225-233.	0.9	12

#	ARTICLE	IF	CITATIONS
355	Affective symptoms and regional cerebral tau burden in early-stage Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1050-1058.	1.3	10
356	Late-Life Anxiety. , 2021, , 226-240.		0
357	Validation of a Brief Screen to Identify Persons With Dementia at Risk for Behavioral Problems. <i>Journal of Applied Gerontology</i> , 2021, 40, 073346482199652.	1.0	2
358	Phenotyping Neuropsychiatric Symptoms Profiles of Alzheimer's Disease Using Cluster Analysis on EEG Power. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 623930.	1.7	4
359	The Potential Role of Herpes Simplex Virus Type 1 and Neuroinflammation in the Pathogenesis of Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 658695.	1.1	22
360	Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	35
362	Photobiomodulation Therapy for Dementia: A Systematic Review of Pre-Clinical and Clinical Studies. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1431-1452.	1.2	27
363	Impaired Knowledge of Social Norms in Dementia and Psychiatric Disorders: Validation of the Social Norms Questionnaire—Dutch Version (SNQ-NL). <i>Assessment</i> , 2021, , 107319112110082.	1.9	2
364	The role of Bcl-2 proteins in modulating neuronal Ca <sup>2+</sup> signaling in health and in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118997.	1.9	31
366	Physical exercise is effective for neuropsychiatric symptoms in Alzheimer's disease: a systematic review. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 447-456.	0.3	5
367	MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer's disease. <i>BMC Neuroscience</i> , 2021, 22, 39.	0.8	25
368	Prevalence of depression, anxiety, and apathy symptoms across dementia stages: A systematic review and meta-analysis. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1330-1344.	1.3	89
369	In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2021, 24, 729-736.	0.6	1
370	A mixed methods study on the manifestations of behavioural symptoms of dementia among veterans with and without posttraumatic stress disorder. <i>Journal of Advanced Nursing</i> , 2021, 77, 3176-3188.	1.5	8
371	Effect of Cognitive Training in Fully Immersive Virtual Reality on Visuospatial Function and Frontal-Occipital Functional Connectivity in Predementia: Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2021, 23, e24526.	2.1	40
372	Gut Microbiota Changes and Their Correlation with Cognitive and Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 583-595.	1.2	59
373	Blood DNA Methylation Levels in the WNT5A Gene Promoter Region: A Potential Biomarker for Agitation in Subjects with Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1601-1611.	1.2	3
374	Risk factors for mild behavioral impairment in non-demented geriatrics: a population-based survey in Taiwan. <i>International Psychogeriatrics</i> , 2021, , 1-9.	0.6	1

#	ARTICLE	IF	CITATIONS
375	Exploration of Rapid Automatized Naming and Standard Visual Tests in Prodromal Alzheimer Disease Detection. <i>Journal of Neuro-Ophthalmology</i> , 2021, Publish Ahead of Print, .	0.4	3
376	System biology and bioinformatics pipeline to identify comorbidities risk association: Neurodegenerative disorder case study. <i>PLoS ONE</i> , 2021, 16, e0250660.	1.1	4
377	Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and l <sup>3</sup> -aminobutyric acid transporters. <i>European Journal of Medicinal Chemistry</i> , 2021, 218, 113397.	2.6	14
378	Impact of Dementia-Related Behavioral Symptoms on Healthcare Resource Use and Caregiver Burden: Real-World Data from Europe and the United States. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1567-1578.	1.2	4
380	Repetitive Transcranial Magnetic Stimulation as an Add-On Treatment for Cognitive Impairment in Alzheimer's Disease and Its Impact on Self-Rated Quality of Life and Caregiver's Burden. <i>Brain Sciences</i> , 2021, 11, 740.	1.1	5
381	Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria. <i>Alzheimer's and Dementia</i> , 2021, 17, 1687-1697.	0.4	8
382	Circular economy monitoring – How to make it apt for biological cycles?. <i>Resources, Conservation and Recycling</i> , 2021, 170, 105563.	5.3	40
383	Quantitative Assessment of Cortical Excitability in Alzheimer's Dementia and Its Association with Clinical Symptoms: A Systematic Review and Meta-Analyses. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 867-891.	1.2	7
384	The Association Between Plasma $\beta$ -Synuclein ( $\beta$ -syn) Protein, Urinary Alzheimer-Associated Neuronal Thread Protein (AD7c-NTP), and Apolipoprotein Epsilon 4 (ApoE $\epsilon$ 4) Alleles and Cognitive Decline in 60 Patients with Alzheimer's Disease Compared with 28 Age-Matched Normal Individuals. <i>Medical Science Monitor</i> , 2021, 27, e932998.	0.5	4
385	Age and gender differences for the behavioral phenotypes of 3xTg alzheimer's disease mice. <i>Brain Research</i> , 2021, 1762, 147437.	1.1	19
386	Feeling valued versus abandoned: Voices of persons who have completed a cognitive assessment. <i>International Journal of Older People Nursing</i> , 2021, 16, e12403.	0.6	4
387	Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer's Disease. <i>Progress in Neurobiology</i> , 2021, 202, 102031.	2.8	46
388	Nighttime Agitation in Persons with Dementia as a Manifestation of Restless Legs Syndrome. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1410-1414.	1.2	8
389	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 423-433.	0.9	11
390	Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation With Disease Stage and Cognitive Deficits. <i>Frontiers in Psychiatry</i> , 2021, 12, 707580.	1.3	21
391	Adjunctive Therapy to Manage Neuropsychiatric Symptoms in Moderate and Severe Dementia: Randomized Clinical Trial Using an Outpatient Version of Tailored Activity Program. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 475-486.	1.2	5
392	Microbiota-Gut-Brain Communication in the SARS-CoV-2 Infection. <i>Cells</i> , 2021, 10, 1993.	1.8	17
393	Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 647-658.	2.9	31

#	ARTICLE	IF	CITATIONS
394	Novel Sulfonamide-Based Carbamates as Selective Inhibitors of BChE. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9447.	1.8	11
395	Assessing Genetic Overlap and Causality Between Blood Plasma Proteins and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1825-1839.	1.2	5
396	Behavioral and Cognitive Response to Selective Serotonin Reuptake Inhibitors in Frontotemporal Lobar Degeneration: A Systematic Review and Meta-analysis. <i>Clinical Neuropharmacology</i> , 2021, 44, 175-183.	0.2	5
397	Early Spatial Memory Impairment in a Double Transgenic Model of Alzheimer's Disease TgF-344 AD. <i>Brain Sciences</i> , 2021, 11, 1300.	1.1	7
398	Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care?. <i>JAMA Neurology</i> , 2021, 78, 1311.	4.5	2
399	Implementation and Evaluation of an Acute Care Multicomponent Intervention for Dementia-Related Behavioral Expressions. <i>Journal of Gerontological Nursing</i> , 2021, 47, 21-30.	0.3	4
400	Pathological methamphetamine exposure triggers the accumulation of neuropathic protein amyloid- $\beta^2$ by inhibiting UCHL1. <i>NeuroToxicology</i> , 2021, 86, 19-25.	1.4	4
401	Depression, cognitive reserve markers, and dementia risk in the general population. <i>Aging and Mental Health</i> , 2022, 26, 2006-2013.	1.5	2
402	Antidepressants in Alzheimer's Disease: A Focus on the Role of Mirtazapine. <i>Pharmaceuticals</i> , 2021, 14, 930.	1.7	16
403	A 3-Gene-Based Diagnostic Signature in Alzheimer's Disease. <i>European Neurology</i> , 2022, 85, 6-13.	0.6	7
404	Biodanza as a Nonpharmacological Dance Movement-Based Treatment in Older People With Alzheimer's Disease. <i>Holistic Nursing Practice</i> , 2021, 35, 264-272.	0.3	3
405	Variability in sub-threshold signaling linked to Alzheimer's disease emerges with age and amyloid plaque deposition in mouse ventral CA1 pyramidal neurons. <i>Neurobiology of Aging</i> , 2021, 106, 207-222.	1.5	5
406	5-HT7 receptors in Alzheimer's disease. <i>Neurochemistry International</i> , 2021, 150, 105185.	1.9	12
407	Neuropsychiatric Manifestations Across Neurological Conditions. , 2022, , 167-175.		0
408	Cognitive profile of aging and dementia. , 2022, , 289-305.		0
409	Grupo virtual de apoio aos cuidadores familiares de idosos com demência no contexto da COVID-19. <i>Brazilian Journal of Occupational Therapy</i> , 0, 29, .	0.5	2
410	Examining Depression Symptoms With/Without Coexisting Anxiety Symptoms in Community-Dwelling Persons With Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2021, 36, 153331752199026.	0.9	2
411	Managing Behavioral and Psychological Symptoms of Dementia. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 315-327.	1.0	27

#	ARTICLE	IF	CITATIONS
416	NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGES. <i>Journal of prevention of Alzheimer's disease, The</i> , 2015, 2, 1-2.	1.5	18
417	PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2015, 2, 1-6.	1.5	12
418	EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTING. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020, 7, 1-8.	1.5	38
419	A FRAMEWORK FOR DEVELOPING PHARMACOTHERAPY FOR AGITATION IN ALZHEIMER'S DISEASE: RECOMMENDATIONS OF THE ISCTM* WORKING GROUP. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020, 7, 1-9.	1.5	5
420	Alzheimer's disease: some pharmacological and non-pharmacological approaches to correcting neuropsychiatric disorders. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2018, 10, 129-134.	0.2	2
421	Neuropsychiatric symptoms and executive function impairments in Alzheimer's disease and vascular dementia: The role of subcortical circuits. <i>Dementia E Neuropsychologia</i> , 2019, 13, 293-298.	0.3	17
422	How non-drug interventions affect the quality of life of patients suffering from progressive cognitive decline and their main caregiver. <i>Aging</i> , 2020, 12, 10754-10771.	1.4	5
423	Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review. <i>Current Alzheimer Research</i> , 2016, 14, 61-75.	0.7	35
424	Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy. <i>Current Neuropharmacology</i> , 2018, 16, 508-518.	1.4	326
425	The Symptoms Targeted for Monitoring in a Web-Based Tracking Tool by Caregivers of People With Dementia and Agitation: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e13360.	2.1	11
426	Multidimensional approach usefulness in early Alzheimer's disease: Advances in clinical practice. <i>Acta Biomedica</i> , 2018, 89, 79-86.	0.2	2
427	The Relationship between Neuropsychiatric Symptoms and Default-Mode Network Connectivity in Alzheimer's Disease. <i>Psychiatry Investigation</i> , 2020, 17, 662-666.	0.7	17
428	What are we trying to prevent in Alzheimer disease?. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 27-34.	1.8	6
429	Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists. <i>Biomolecules</i> , 2021, 11, 3.	1.8	4
430	Antipsychotics for Neuropsychiatric Symptoms of Dementia—Safety and Efficacy in the Context of Informed Consent. <i>Psychiatric Annals</i> , 2015, 45, .	0.1	6
431	Managing Challenging Behaviors of Dementia in Veterans: Identifying and Changing Activators and Consequences Using STAR-VA. <i>Journal of Gerontological Nursing</i> , 2017, 43, 33-43.	0.3	12
432	Nonpharmacological Strategies Used By Family Caregivers of Persons With Alzheimer's Disease and Related Dementias as Presented in Blogs. <i>Journal of Gerontological Nursing</i> , 2019, 45, 25-35.	0.3	7
433	Preparation and Characterization of Microglia-Like Cells Derived from Rat, Mouse, and Human Bone Marrow Cells for Therapeutic Strategy of Alzheimer's Disease. <i>Journal of Addiction Research &amp; Therapy</i> , 0, s5, .	0.2	3



#	ARTICLE	IF	CITATIONS
434	Activated Caspase-3 and Neurodegeneration and Synaptic Plasticity in Alzheimer's Disease. <i>Advances in Alzheimer's Disease</i> , 2015, 04, 63-77.	0.3	12
435	A Comparison of the Behavioral and Psychological Symptoms of Dementia (BPSD) in Early-Onset and Late-Onset Alzheimer's Disease - A Study from South East Asia (Kashmir, India). <i>Cureus</i> , 2016, 8, e625.	0.2	15
436	Antipsychotic discontinuation after the initiation of selective serotonin reuptake inhibitors therapy for the treatment of behavioral and psychological symptoms associated with dementia. <i>Mental Health Clinician</i> , 2018, 8, 122-126.	0.5	4
437	Antipsychotic use in elderly patients with dementia: Efficacy and safety concerns. <i>Mental Health Clinician</i> , 2014, 4, 170-176.	0.5	5
438	The Positive Effects of Pet Ownership on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1669-1675.	1.2	6
439	The doll therapy as a first line treatment for behavioral and psychologic symptoms of dementia in nursing homes residents: a randomized, controlled study. <i>BMC Geriatrics</i> , 2021, 21, 545.	1.1	7
440	Predictors of Caregiver Burden of Patients with Alzheimer Disease Attending Day-Care Centres. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10707.	1.2	4
441	Interactions of comorbid neuropsychiatric subsyndromes with neurodegenerative and cerebrovascular pathologies on cognition. <i>Neurobiology of Aging</i> , 2022, 109, 239-246.	1.5	2
442	Sesamol Attenuates Amyloid Peptide Accumulation and Cognitive Deficits in APP/PS1 Mice: The Mediating Role of the Gut-Brain Axis. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 12717-12729.	2.4	29
443	Dementias and Other Amnestic Disorders. , 2014, , 1-9.		0
444	Neuropsychiatric Symptoms in Alzheimer's Disease Patients: Improving the Diagnosis. , 2014, 04, .		1
445	COMMUNICATION DISORDERS OF ACTIVE MILITARY PERSONNEL WITH TRAUMATIC BRAIN INJURY - A REVIEW STUDY. <i>Military Medical Science Letters (Vojenske Zdravotnicke Listy)</i> , 2015, 84, 170-176.	0.2	0
446	Biomarkers in Mild Stages of Alzheimer's disease: Utility in clinical practice and their relation with nutritional and lifestyle factors. <i>Functional Foods in Health and Disease</i> , 2016, 6, 627.	0.3	0
447	Insufficiency of Cellular Energy (ICE) May Precede Neurodegeneration in Alzheimer's Disease and Be Treatable via the Alternative Cellular Energy (ACE) Pathway. <i>Advances in Alzheimer's Disease</i> , 2017, 06, 1-12.	0.3	6
448	Alzheimer Disease. , 2017, , .		0
449	Psychological and Neuropsychological Testing. , 2018, , 81-90.		0
451	A Study on the Status of Psychobehavioral Symptoms in Patients with Alzheimer's Disease. <i>International Journal of Psychiatry and Neurology</i> , 2019, 08, 31-40.	0.1	0
453	Huzurevinde Yaşayan Alzheimer's Bireylerin Gıda Yaşam Aktivitelerindeki Fonksiyonel Duruma Etki Eden Faktörlerin İncelenmesi. <i>Ergoterapi Ve Rehabilitasyon Dergisi</i> , 2019, 7, 165-170.	0.1	0

#	ARTICLE	IF	CITATIONS
454	Behavioral Symptoms of Dementia in Latinos: Pharmacological, Non-pharmacological, and Ethnocultural Healthcare Interventions. , 2020, , 187-203.		0
455	Immune system and quality of life following aerobic exercise versus resistance exercise training among Alzheimer's. Archives of Asthma Allergy and Immunology, 2020, 4, 003-008.	0.1	0
457	Neuropsychiatric symptoms, quality of life and caregivers' burden in dementia. Open Medicine (Poland), 2020, 15, 905-914.	0.6	8
458	Factors Associated With Behavioral and Psychological Symptoms of Dementia: Prospective Observational Study Using Actigraphy. Journal of Medical Internet Research, 2021, 23, e29001.	2.1	12
459	Late-onset obsessive-compulsive disorder as the initial manifestation of possible behavioural variant Alzheimer's disease. Cognitive Neuropsychiatry, 2022, 27, 11-19.	0.7	4
460	Alzheimer's disease: Causes, treatment & basic science review. IP International Journal of Comprehensive and Advanced Pharmacology, 2021, 6, 108-116.	0.1	0
461	Understanding help-seeking decisions in people with subjective cognitive decline: A systematic review of qualitative studies. Geriatric Nursing, 2021, 42, 1507-1516.	0.9	4
462	Daily garden use and quality of life in persons with advanced dementia living in a nursing home: A feasibility study. Nursing Open, 2021, 8, 1243-1253.	1.1	3
463	Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD). Journal of the American Geriatrics Society, 2021, 69, 955-963.	1.3	9
464	Sleep Behaviors in Persons With Alzheimer's Disease: Associations With Caregiver Sleep and Affect. Journal of Applied Gerontology, 2022, 41, 295-305.	1.0	9
465	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0
466	RhoA/Rock2/Limk1/cofilin1 pathway is involved in attenuation of neuronal dendritic spine loss by paeonol in the frontal cortex of D-galactose and aluminum-induced Alzheimer's disease-like rat model. Acta Neurobiologiae Experimentalis, 2020, 80, 225-244.	0.4	13
467	Block copolymers in Alzheimer's disease therapy: A perspective to revolutionize biomaterials. Journal of Controlled Release, 2021, 340, 271-281.	4.8	17
468	Plasma Total Tau and Neurobehavioral Symptoms of Cognitive Decline in Cognitively Normal Older Adults. Frontiers in Psychology, 2021, 12, 774049.	1.1	4
469	Contribution of Iranian researchers in Alzheimer's disease research: A 10 years scientometric analysis. Journal of Diabetes and Metabolic Disorders, 2021, 20, 2025-2036.	0.8	0
470	Prevalence of mild behavioural impairment domains: a meta-analysis. Psychogeriatrics, 2022, 22, 84-98.	0.6	10
471	Characterization of Alzheimer's Disease-Associated Excitatory Neurons via Single-Cell RNA Sequencing Analysis. Frontiers in Aging Neuroscience, 2021, 13, 742176.	1.7	7
472	Long-term neuropsychiatric symptoms in spontaneous intracerebral haemorrhage survivors. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 232-237.	0.9	11

#	ARTICLE	IF	CITATIONS
474	A biopsychosocial interpretation of the Neuropsychiatric Inventory â€“ Nursing Home assessment: reconceptualising psychiatric symptom attributions. <i>BJPsych Open</i> , 2020, 6, e137.	0.3	1
476	Apathy and related executive syndromes in dementia associated with Parkinson's disease and in Alzheimer's disease. <i>Behavioural Neurology</i> , 2013, 27, 515-22.	1.1	15
477	Pharmacotherapy of neuropsychiatric symptoms of dementia. <i>P and T</i> , 2015, 40, 284-7.	1.0	1
478	Evidence-based Non-pharmacologic Interventions for Managing Neuropsychiatric Symptoms and Mental Health Issues in Residents in Assisted Living. <i>Seniors Housing &amp; Care Journal</i> , 2017, 25, 71-83.	0.5	0
480	Acrolein, an endogenous aldehyde induces Alzheimer's disease-like pathologies in mice: A new sporadic AD animal model. <i>Pharmacological Research</i> , 2022, 175, 106003.	3.1	14
481	Hybrid Feature Selection Framework for the Parkinson Imbalanced Dataset Prediction Problem. <i>Medicina (Lithuania)</i> , 2021, 57, 1217.	0.8	13
482	Automated multi-dose dispensing in persons with and without Alzheimerâ€™s diseaseâ€™ impacts on pharmacotherapy. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 513-521.	0.8	0
483	The Moderating Effects of Personal Resources on Caregiver Burden in Carers of Alzheimer's Patients. <i>Frontiers in Psychiatry</i> , 2021, 12, 772050.	1.3	3
484	A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 691-699.	1.2	30
485	In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimerâ€™s disease phases. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 187.	3.0	29
486	Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: mediation by amyloid pathology. <i>Translational Psychiatry</i> , 2021, 11, 577.	2.4	11
487	Psychedelics as Novel Therapeutics in Alzheimerâ€™s Disease: Rationale and Potential Mechanisms. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 287-317.	0.8	11
488	Psychosis in Alzheimer disease â€™ mechanisms, genetics and therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2022, 18, 131-144.	4.9	62
489	Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1219.	1.8	20
490	A qualitative exploration of living with dementia in supported living environments using a peer researcher approach. <i>Aging and Health Research</i> , 2022, 2, 100055.	0.5	2
491	Exploring how caregivers for people living with dementia use strategies to overcome work system constraints. <i>Applied Ergonomics</i> , 2022, 101, 103689.	1.7	0
494	Clinical Trajectories of Neuropsychiatric Symptoms in Mild-Moderate to Advanced Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 861-875.	1.2	4
495	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465.	1.3	3

#	ARTICLE	IF	CITATIONS
496	New Strategies for the Treatment of Neuropsychiatric Disorders Based on Reelin Dysfunction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1829.	1.8	10
497	Sleep and dementia. , 2022, , .		0
498	Specific depression dimensions are associated with a faster rate of cognitive decline in older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12268.	1.2	0
499	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2022, 47, 1128-1136.	2.8	30
500	Targeted Suppression of Lipoprotein Receptor LSR in Astrocytes Leads to Olfactory and Memory Deficits in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2049.	1.8	3
501	Active music therapy in dementia: results from an open-label trial. <i>Jornal Brasileiro De Psiquiatria</i> , 0, , .	0.2	0
503	Education level is associated with neuropsychiatric symptoms in patients with amnesic mild cognitive impairment. <i>Psychogeriatrics</i> , 2022, 22, 343-352.	0.6	3
504	Association of Variation in Behavioral Symptoms With Initial Cognitive Phenotype in Adults With Dementia Confirmed by Neuropathology. <i>JAMA Network Open</i> , 2022, 5, e220729.	2.8	11
505	Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022, 34, 214-223.	0.9	1
506	Polygenic Risk Score Effectively Predicts Depression Onset in Alzheimer's Disease Based on Major Depressive Disorder Risk Variants. <i>Frontiers in Neuroscience</i> , 2022, 16, 827447.	1.4	4
507	Enhanced Association of Tau Pathology and Cognitive Impairment in Mild Cognitive Impairment Subjects with Behavior Symptoms. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 557-568.	1.2	3
508	Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME) in home care services: a cluster randomized feasibility trial. <i>BMC Health Services Research</i> , 2022, 22, 415.	0.9	1
509	Design, synthesis and biological evaluation of novel <i>N</i> -phosphorylated and <i>O</i> -phosphorylated tacrine derivatives as potential drugs against Alzheimer's disease. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1012-1022.	2.5	11
510	The Role of Vascular Risk Factors in Biomarker-Based AT(N) Groups: A German-Dutch Memory Clinic Study. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 185-195.	1.2	6
511	Virtual Behavioural Medicine Program: A Novel Model of Care for Neuropsychiatric Symptoms in Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1169-1184.	1.2	2
512	Age-related deficits in working memory in 5xFAD mice in the Hebb-Williams maze. <i>Behavioural Brain Research</i> , 2022, 424, 113806.	1.2	7
513	Towards Defining the Neuroanatomical Basis of Late-Onset Psychiatric Symptoms. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 751-762.	1.2	2
514	sTREM2 mediates the associations of minimal depressive symptoms with amyloid pathology in prodromal Alzheimer's disease: The CABLE study. <i>Translational Psychiatry</i> , 2022, 12, 140.	2.4	3

#	ARTICLE	IF	CITATIONS
515	Assessments of prolonged effects of desflurane and sevoflurane on motor learning deficits in aged AppNL-G-F/NL-G-F mice. <i>Molecular Brain</i> , 2022, 15, 32.	1.3	2
517	Alteration of Neural Pathways and Its Implications in Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 845.	1.4	8
518	Neuropsychiatric Inventory Questionnaire Assessed Nighttime Behaviors in Cognitively Asymptomatic Patients with Pathologically Confirmed Alzheimer's Disease Predict More Rapid Cognitive Deterioration. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1137-1147.	1.2	3
519	Exercise Dosage in Reducing the Risk of Dementia Development: Mode, Duration, and Intensity A Narrative Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13331.	1.2	12
520	The severity of neuropsychiatric symptoms is higher in early-onset than late-onset Alzheimer's disease. <i>European Journal of Neurology</i> , 2022, 29, 957-967.	1.7	16
521	Recent Studies on Berry Bioactives and Their Health-Promoting Roles. <i>Molecules</i> , 2022, 27, 108.	1.7	4
523	Alzheimer's Disease: A Silent Pandemic A Systematic Review on the Situation and Patent Landscape of the Diagnosis. <i>Recent Patents on Biotechnology</i> , 2022, 16, .	0.4	0
524	Discovery of Novel Drug Candidates for Alzheimer's Disease by Molecular Network Modeling. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 850217.	1.7	4
525	The Effect of Gut Microbe Dysbiosis on the Pathogenesis of Alzheimer's Disease (AD) and Related Conditions. <i>Current Alzheimer Research</i> , 2022, 19, 274-284.	0.7	3
526	Deep brain stimulation for psychiatric disorders and behavioral/cognitive-related indications: Review of the literature and implications for treatment. <i>Journal of the Neurological Sciences</i> , 2022, 437, 120253.	0.3	3
533	Adult hippocampal neurogenesis and its impairment in Alzheimer's disease. <i>Zoological Research</i> , 2022, 43, 481-496.	0.9	16
534	Transcranial Direct Current Stimulation Enhances Cognitive Function in Patients with Mild Cognitive Impairment and Early/Mid Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Brain Sciences</i> , 2022, 12, 562.	1.1	17
535	Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer's Disease: A Review. <i>Frontiers in Human Neuroscience</i> , 2022, 16, 866434.	1.0	25
536	Daily Physical Activity Patterns as a Window on Cognitive Diagnosis in the Baltimore Longitudinal Study of Aging (BLSA). <i>Journal of Alzheimer's Disease</i> , 2022, 88, 459-469.	1.2	5
537	Shared pathophysiology: Understanding stroke and Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 2022, 218, 107306.	0.6	9
539	Cognitive Impairment in Alzheimer's and Metabolic Diseases: A Catecholaminergic Hypothesis. <i>Neuroscience</i> , 2022, , .	1.1	6
540	Neurocognitive Disorders. , 2022, , .		0
541	Ameliorative Effects of Phytomedicines on Alzheimer's Patients. <i>Current Alzheimer Research</i> , 2022, 19, 420-439.	0.7	2

#	ARTICLE	IF	CITATIONS
542	Ending Choose-Your-Own-Adventure Care for Agitation in Dementia. <i>International Psychogeriatrics</i> , 0, , 1-6.	0.6	1
543	Emerging Neuropsychiatric Symptoms May Represent an Early Manifestation of Preclinical Alzheimer's Disease. <i>Biological Psychiatry</i> , 2022, 92, e1-e3.	0.7	0
544	ATP-sensitive potassium channels: A double-edged sword in neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2022, 80, 101676.	5.0	7
545	A human factors and ergonomics approach to conceptualizing care work among caregivers of people with dementia. <i>Applied Ergonomics</i> , 2022, 104, 103820.	1.7	0
546	The recognition and management of neuropsychiatric symptoms in early Alzheimer's disease: a qualitative study among Dutch memory clinic physicians. <i>Psychogeriatrics</i> , 0, , .	0.6	4
547	Anthocyanin-rich blackcurrant extract improves long-term memory impairment and emotional abnormality in senescence-accelerated mice. <i>Journal of Food Biochemistry</i> , 2022, 46, .	1.2	6
548	Relations of neuropsychiatric symptoms with disease stage, sex, and daily function in mild cognitive impairment and dementia due to Alzheimer's disease: A cross-sectional study. <i>Journal of Psychosomatic Research</i> , 2022, 161, 110994.	1.2	6
549	Neurocognitive health of older adults experiencing homelessness in Oakland, California. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3
550	Sirtuins and cognition: implications for learning and memory in neurological disorders. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	12
551	Neurologic Music Therapy with a Habilitative Approach for Older Adults with Dementia: A Feasibility Study. <i>Music Therapy Perspectives</i> , 2022, 40, 76-83.	0.2	1
552	Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	16
553	Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer's disease. <i>Human Brain Mapping</i> , 2023, 44, 119-130.	1.9	7
554	Depression in a Patient With Alzheimer Disease. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.4	0
555	Effectiveness of cognitive stimulation therapy (CST) on cognition, quality of life and neuropsychiatric symptoms for patients living with dementia: A meta-analysis. <i>Geriatric Nursing</i> , 2022, 47, 201-210.	0.9	11
556	Effects of chronic vagal nerve stimulation in the treatment of $\beta$ -amyloid-induced neuropsychiatric symptoms. <i>European Journal of Pharmacology</i> , 2022, 931, 175179.	1.7	5
557	Recent developments in the synthesis of pyridine analogues as a potent anti-Alzheimer's therapeutic leads. , 2023, , 411-444.		1
558	Characterization of Apathy-Like Behaviors in the 5xFAD Mouse Model of Alzheimer's Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
559	Musical Bridges to Memory. <i>Alzheimer Disease and Associated Disorders</i> , 2022, 36, 312-318.	0.6	2

#	ARTICLE	IF	CITATIONS
560	Monitoring daily well-being and meaning-making tendencies among adult child working dementia caregivers: validating an experience sampling study protocol. <i>BMC Geriatrics</i> , 2022, 22, .	1.1	0
561	<i>Pinus halepensis</i> Essential Oil Ameliorates A $\beta$ <sup>21-42</sup> -Induced Brain Injury by Diminishing Anxiety, Oxidative Stress, and Neuroinflammation in Rats. <i>Biomedicines</i> , 2022, 10, 2300.	1.4	2
562	Boosting amygdaloid GABAergic and neurotrophic machinery via dapagliflozin-enhanced LKB1/AMPK signaling in anxious demented rats. <i>Life Sciences</i> , 2022, 310, 121002.	2.0	8
563	Effects of Reminiscence Therapy on Cognition, Depression and Quality of Life in Elderly People with Alzheimer's Disease: A Systematic Review of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 5752.	1.0	11
564	Roles of neuroligins in central nervous system development: focus on glial neuroligins and neuron neuroligins. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
565	Preliminary Validation Study of the French-Quebec Version of the Mild Behavioral Impairment Checklist. <i>Cognitive and Behavioral Neurology</i> , 2023, 36, 9-18.	0.5	2
566	Phyto-therapeutic and nanomedicinal approaches: A new hope for management of Alzheimer's disease. <i>International Journal of Pharmaceutics</i> , 2022, 627, 122213.	2.6	0
567	The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	12
568	Sex Modifies the Associations of APOE $\epsilon$ 4 with Neuropsychiatric Symptom Burden in Both At-Risk and Clinical Cohorts of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1571-1588.	1.2	2
569	Blood plasma protein profiles of neuropsychiatric symptoms and related cognitive decline in older people. <i>Journal of Neurochemistry</i> , 2023, 164, 242-254.	2.1	5
570	Targeting Alzheimer's Disease: The Critical Crosstalk between the Liver and Brain. <i>Nutrients</i> , 2022, 14, 4298.	1.7	13
571	May phyto-phenolics alleviate aflatoxins-induced health challenges? A holistic insight on current landscape and future prospects. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	9
572	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	98
573	Improving community health care systems' early detection of cognitive decline and dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 2375-2381.	0.4	1
574	Ovariectomy-induced hormone deprivation aggravates A $\beta$ <sup>21-42</sup> deposition in the basolateral amygdala and cholinergic fiber loss in the cortex but not cognitive behavioral symptoms in a triple transgenic mouse model of Alzheimer's disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
575	Tactile stimulation improves cognition, motor, and anxiety-like behaviors and attenuates the Alzheimer's disease pathology in adult APP <sup>NL-GF/NL-GF</sup> mice. <i>Synapse</i> , 2023, 77, .	0.6	2
576	The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 701-714.	0.9	1
577	The Willingness to Help People With Dementia Symptoms Among Four Occupation Practitioners in Macao. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2022, 37, 153331752211391.	0.9	0

#	ARTICLE	IF	CITATIONS
578	Differential Gene Expression and DNA Methylation in the Risk of Depression in LOAD Patients. <i>Biomolecules</i> , 2022, 12, 1679.	1.8	1
579	The effectiveness of non-pharmacological interventions using information and communication technologies for behavioral and psychological symptoms of dementia: A systematic review and meta-analysis. <i>International Journal of Nursing Studies</i> , 2023, 138, 104392.	2.5	12
580	Behavioral and psycho-social impairments among people living with dementia and their management by caregivers in South-Western Uganda: a qualitative study. <i>Aging and Mental Health</i> , 2023, 27, 1938-1945.	1.5	0
581	Design, synthesis, and preliminary evaluation of [18F]-aryl flurosulfates PET radiotracers via SuFEx methods for $\beta$ -amyloid plaques in Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 75, 117087.	1.4	3
582	Light Therapy to Improve Sleep Quality in Older Adults Living in Residential Long-Term Care: A Systematic Review. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 65-74.e1.	1.2	3
583	Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2023, 84, 101819.	5.0	9
584	Exercise interventions ameliorate neuropsychiatric symptoms in dementia: A meta-analysis. <i>Mental Health and Physical Activity</i> , 2023, 24, 100496.	0.9	0
585	Upregulation of Ca <sup>2+</sup> -binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer's disease in Tg2576 mice. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	16
586	Effect of a multimodal non-pharmacological intervention on older people with dementia: a single-case experimental design study. <i>BMC Geriatrics</i> , 2022, 22, .	1.1	1
587	Healthcare use patterns before Alzheimer's disease and related diseases identification and future healthcare trajectory. <i>International Journal of Geriatric Psychiatry</i> , 2023, 38, .	1.3	0
588	The role of ethnicity, biological sex, and psychotropic agents in early and late onset Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	0
589	â€œI Will Be Healthyâ€: Ideal Self in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 775-781.	1.2	0
590	Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer's disease. <i>Neuropharmacology</i> , 2023, 226, 109371.	2.0	9
591	Antidepressants as a potential candidate to reduce microglia activation in neurodegenerative diseases. A systematic review and meta-analysis of preclinical studies. <i>Journal of Affective Disorders Reports</i> , 2023, 11, 100465.	0.9	0
592	A Review on Phyto-Therapeutic Approaches in Alzheimer's Disease. <i>Journal of Functional Biomaterials</i> , 2023, 14, 50.	1.8	5
593	Gut Microbiota, Alzheimer and Psychiatric Diseases: Unveiling the Relationships and Treatment Options. <i>Healthy Ageing and Longevity</i> , 2023, , 279-333.	0.2	0
594	Ethics in Geriatric Mental Health. , 2022, , .		0
595	Dementia and Mild Neurocognitive Disorders. , 2022, , .		0



#	ARTICLE	IF	CITATIONS
596	Schizophrenia Spectrum and Other Psychotic Disorders. , 2022, , .		0
597	Genomics in Geriatric Psychiatry. , 2022, , .		0
599	Individual and Group Psychotherapy. , 2022, , .		0
600	Sexuality and Aging. , 2022, , .		0
601	Use of the Laboratory in the Diagnostic Workup of Older Adults. , 2022, , .		0
602	Anxiety, Obsessive-Compulsive, and Trauma-Related Disorders. , 2022, , .		1
603	Working With Families of Older Adults. , 2022, , .		0
604	Somatic Symptom and Related Disorders. , 2022, , .		0
606	Neuropsychological Assessment of Late-Life Cognitive Disorders. , 2022, , .		0
607	Sleep and Circadian Rhythm Sleep-Wake Disorders. , 2022, , .		0
608	Bipolar and Related Disorders. , 2022, , .		0
609	The Psychiatric Interview of Older Adults. , 2022, , .		0
611	Substance-Related and Addictive Disorders. , 2022, , .		0
613	Electroconvulsive Therapy and Other Forms of Brain Stimulation. , 2022, , .		0
614	Depressive Disorders. , 2022, , .		0
615	Physiological and Clinical Considerations of Geriatric Patient Care. , 2022, , .		0
616	Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .		0
618	Use of Technology in Geriatric Psychiatry. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
619	Agitation in Older Adults. , 2022, , .		0
620	Clinical Psychiatry in the Nursing Home. , 2022, , .		0
622	Kan bruk av atferd- og dÅgnrytmeregistreringsskjema predikere aggresjon og irritasjon hos pasienter innlagt i en alderspsykiatrisk dÅgnavdeling?. Nordisk Sygeplejeforskning, 2023, 13, 1-23.	0.1	0
623	A Review on Recent Approaches on Molecular Docking Studies of Novel Compounds Targeting Acetylcholinesterase in Alzheimer Disease. Molecules, 2023, 28, 1084.	1.7	16
624	Behavioral and Psychological Symptoms of Dementia: Prevalence, Symptom Severity, and Caregiver Distress in South-Western Ugandaâ€”A Quantitative Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2023, 20, 2336.	1.2	1
625	Microglial Activation in Metal Neurotoxicity: Impact in Neurodegenerative Diseases. BioMed Research International, 2023, 2023, 1-27.	0.9	8
627	Pharmacologic treatment of depression in Alzheimerâ€™s disease. International Clinical Psychopharmacology, 2023, 38, 81-88.	0.9	4
628	Human tau-overexpressing mice recapitulate brainstem involvement and neuropsychiatric features of early Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2023, 11, .	2.4	6
629	Molecular mechanisms of ferroptosis and their involvement in brain diseases. , 2023, 244, 108373.		42
630	Characterization of apathy-like behaviors in the 5xFAD mouse model of Alzheimerâ€™s disease. Neurobiology of Aging, 2023, 126, 113-122.	1.5	4
631	The role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases. Ageing Research Reviews, 2023, 87, 101907.	5.0	12
632	An Intervention on Anxiety Symptoms in Moderate Alzheimerâ€™s Disease through Virtual Reality: A Feasibility Study and Lessons Learned. International Journal of Environmental Research and Public Health, 2023, 20, 2727.	1.2	5
633	Impact of behavioral and psychological symptoms of dementia (BPSD) in institutionalized people. MOJ Gerontology & Geriatrics, 2019, 4, 233-239.	0.1	0
634	Intranasal Lipid Nanoparticles Containing Bioactive Compounds Obtained from Marine Sources to Manage Neurodegenerative Diseases. Pharmaceuticals, 2023, 16, 311.	1.7	2
635	Physical Exercise as a Nonpharmacological Intervention for the Treatment of Neuropsychiatric Symptoms in Persons With Dementia. Alzheimer Disease and Associated Disorders, 2023, 37, 73-81.	0.6	0
636	Behavioural subphenotypes and their anatomic correlates in neurodegenerative disease. Brain Communications, 2023, 5, .	1.5	3
637	Neuropsychiatric Manifestations in Alzheimerâ€™s Disease Patients: Genetics and Treatment Options. CNS and Neurological Disorders - Drug Targets, 2023, 22, .	0.8	0
638	Quality of Nursing Homes Among ADRD Residents Newly Admitted From the Community: Does Race Matter?. Journal of the American Medical Directors Association, 2023, , .	1.2	0

#	ARTICLE	IF	CITATIONS
640	LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features. <i>Cells</i> , 2023, 12, 805.	1.8	3
641	Assessing the Role of Past Depression in Patients with Mild Cognitive Impairment, with and without Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 1219-1227.	1.2	0
642	Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-12.	1.2	0
643	The Effects of Light Therapy on Sleep, Agitation and Depression in People With Dementia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2023, 38, 153331752311606.	0.9	5
647	Influence of affective states on informant impression of neuropsychiatric symptoms in people living with MCI. <i>Aging and Mental Health</i> , 2023, 27, 2128-2133.	1.5	0
659	Autophagy Mechanisms for Brain Recovery. Keep It Clean, Keep It Alive. <i>Contemporary Clinical Neuroscience</i> , 2023, , 41-76.	0.3	0
660	Neurodegenerative Disorders/Dementia. , 2023, , 215-226.		0
669	Fatigue in Alzheimer's disease: biological basis and clinical management—a narrative review. <i>Aging Clinical and Experimental Research</i> , 2023, 35, 1981-1989.	1.4	2
671	Escapad—Dance Serious Game: Designing a Therapeutic Tool for Elderly with Mild Cognitive Impairment. <i>Lecture Notes in Computer Science</i> , 2023, , 222-236.	1.0	0
688	Lipid Profiling in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 281-287.	0.8	0
694	Diagnostic performance of MRI radiomics for classification of Alzheimer's disease, mild cognitive impairment, and normal subjects: a systematic review and meta-analysis. <i>Aging Clinical and Experimental Research</i> , 2023, 35, 2333-2348.	1.4	1
703	Pathogenesis of Depression in Alzheimer's Disease. <i>Neurochemical Research</i> , 2024, 49, 548-556.	1.6	1
713	A Review on Machine Learning and Deep Learning Based Approaches in Detection and Grading of Alzheimer's Disease. <i>Communications in Computer and Information Science</i> , 2024, , 1-13.	0.4	0
720	Alzheimer's Disease and Drug Targets. , 2023, , 3-16.		0
727	Distinguishing features of depression in dementia from primary psychiatric disease. <i>Discover Mental Health</i> , 2024, 4, .	1.0	1
728	Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives. <i>Molecular Psychiatry</i> , 0, , .	4.1	0